FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W192179675> ?p ?o ?g. }

• W192179675 endingPage "4335" @default.
• W192179675 startingPage "4325" @default.
• W192179675 abstract "Abstract Acute myeloid leukemia (AML) occurs as the result of malignant transformation in a hematopoietic progenitor cell, which proliferates to form an accumulation of AML blasts. Only a minority of these AML cells are capable of proliferation in vitro, suggesting that AML cells may be organized in a hierarchy, with only the most primitive of these cells capable of maintaining the leukemic clone. To further investigate this hypothesis, we have evaluated a strategy for purifying these primitive cells based on surface antigen expression. As an in vitro endpoint, we have determined the phenotype of AML progenitor cells which are capable of producing AML colony-forming cells (CFU) for up to 8 weeks in suspension culture (SC) and compared the phenotype with that of cells which reproduce AML in nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice. AML cells were fluorescence-activated cell sorted (FACS) for coexpression of CD34 and CD71, CD38, and/or HLA-DR and the subfractions were assayed in vitro and in vivo at various cell doses to estimate purification. While the majority of primary AML CFU lacked expression of CD34, most cells capable of producing CFU after 2 to 8 weeks in SC were CD34+/CD71−. HLA-DR expression was heterogeneous on cells producing CFU after 2 to 4 weeks. However, after 6 to 8 weeks in SC, the majority of CFU were derived from CD34+/HLA-DR− cells. Similarly, the majority of cells capable of long-term CFU production from SC were CD34+/CD38−. Most cells that were capable of engrafting NOD/SCID mice were also CD34+/CD71− and CD34+/HLA-DR−. Engraftment was not achieved with CD34+/CD71+ or HLA-DR+subfractions, however, in two patients, both the CD34+and CD34− subfractions were capable of engrafting the NOD/SCID mice. A three-color sorting strategy combining these antigens allowed approximately a 2-log purification of these NOD/SCID leukemia initiating cells, with engraftment achieved using as few as 400 cells in one experiment. Phenotyping studies suggest even higher purification could be achieved by combining lack of CD38 expression with the CD34+/CD71− or CD34+/HLA DR− phenotype. These results suggest that most AML cells capable of long-term proliferation in vitro and in vivo share the CD34+/CD71−/HLA-DR− phenotype with normal stem cells. Our data suggests that in this group of patients the leukemic transformation has occurred in a primitive progenitor, as defined by phenotype, with some degree of subsequent differentiation as defined by functional assays." @default.
• W192179675 created "2016-06-24" @default.
• W192179675 creator A5022065039 @default.
• W192179675 creator A5065900158 @default.
• W192179675 creator A5069133845 @default.
• W192179675 date "1998-12-01" @default.
• W192179675 modified "2023-10-14" @default.
• W192179675 title "Most Acute Myeloid Leukemia Progenitor Cells With Long-Term Proliferative Ability In Vitro and In Vivo Have the Phenotype CD34+/CD71−/HLA-DR−" @default.
• W192179675 cites W109176542 @default.
• W192179675 cites W1538762819 @default.
• W192179675 cites W174442591 @default.
• W192179675 cites W1953971027 @default.
• W192179675 cites W1975188468 @default.
• W192179675 cites W2004543423 @default.
• W192179675 cites W2009556222 @default.
• W192179675 cites W2009886857 @default.
• W192179675 cites W2026351957 @default.
• W192179675 cites W2030641259 @default.
• W192179675 cites W2034537357 @default.
• W192179675 cites W2035152288 @default.
• W192179675 cites W2055222014 @default.
• W192179675 cites W2090982381 @default.
• W192179675 cites W2137696432 @default.
• W192179675 cites W2146018570 @default.
• W192179675 cites W2218895233 @default.
• W192179675 cites W2405727807 @default.
• W192179675 cites W2409120826 @default.
• W192179675 cites W305410183 @default.
• W192179675 cites W4239317073 @default.
• W192179675 cites W74017565 @default.
• W192179675 cites W99410290 @default.
• W192179675 doi "https://doi.org/10.1182/blood.v92.11.4325" @default.
• W192179675 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9834239" @default.
• W192179675 hasPublicationYear "1998" @default.
• W192179675 type Work @default.
• W192179675 sameAs 192179675 @default.
• W192179675 citedByCount "229" @default.
• W192179675 countsByYear W1921796752012 @default.
• W192179675 countsByYear W1921796752013 @default.
• W192179675 countsByYear W1921796752014 @default.
• W192179675 countsByYear W1921796752015 @default.
• W192179675 countsByYear W1921796752016 @default.
• W192179675 countsByYear W1921796752017 @default.
• W192179675 countsByYear W1921796752018 @default.
• W192179675 countsByYear W1921796752019 @default.
• W192179675 countsByYear W1921796752020 @default.
• W192179675 countsByYear W1921796752021 @default.
• W192179675 countsByYear W1921796752022 @default.
• W192179675 countsByYear W1921796752023 @default.
• W192179675 crossrefType "journal-article" @default.
• W192179675 hasAuthorship W192179675A5022065039 @default.
• W192179675 hasAuthorship W192179675A5065900158 @default.
• W192179675 hasAuthorship W192179675A5069133845 @default.
• W192179675 hasConcept C10205521 @default.
• W192179675 hasConcept C109159458 @default.
• W192179675 hasConcept C129374314 @default.
• W192179675 hasConcept C131665280 @default.
• W192179675 hasConcept C147483822 @default.
• W192179675 hasConcept C150903083 @default.
• W192179675 hasConcept C153911025 @default.
• W192179675 hasConcept C159912055 @default.
• W192179675 hasConcept C167672396 @default.
• W192179675 hasConcept C201750760 @default.
• W192179675 hasConcept C203014093 @default.
• W192179675 hasConcept C207001950 @default.
• W192179675 hasConcept C2778461978 @default.
• W192179675 hasConcept C2778729363 @default.
• W192179675 hasConcept C2779282312 @default.
• W192179675 hasConcept C2779468541 @default.
• W192179675 hasConcept C28328180 @default.
• W192179675 hasConcept C502942594 @default.
• W192179675 hasConcept C54355233 @default.
• W192179675 hasConcept C552990157 @default.
• W192179675 hasConcept C81089528 @default.
• W192179675 hasConcept C86803240 @default.
• W192179675 hasConcept C95444343 @default.
• W192179675 hasConceptScore W192179675C10205521 @default.
• W192179675 hasConceptScore W192179675C109159458 @default.
• W192179675 hasConceptScore W192179675C129374314 @default.
• W192179675 hasConceptScore W192179675C131665280 @default.
• W192179675 hasConceptScore W192179675C147483822 @default.
• W192179675 hasConceptScore W192179675C150903083 @default.
• W192179675 hasConceptScore W192179675C153911025 @default.
• W192179675 hasConceptScore W192179675C159912055 @default.
• W192179675 hasConceptScore W192179675C167672396 @default.
• W192179675 hasConceptScore W192179675C201750760 @default.
• W192179675 hasConceptScore W192179675C203014093 @default.
• W192179675 hasConceptScore W192179675C207001950 @default.
• W192179675 hasConceptScore W192179675C2778461978 @default.
• W192179675 hasConceptScore W192179675C2778729363 @default.
• W192179675 hasConceptScore W192179675C2779282312 @default.
• W192179675 hasConceptScore W192179675C2779468541 @default.
• W192179675 hasConceptScore W192179675C28328180 @default.
• W192179675 hasConceptScore W192179675C502942594 @default.
• W192179675 hasConceptScore W192179675C54355233 @default.
• W192179675 hasConceptScore W192179675C552990157 @default.
• W192179675 hasConceptScore W192179675C81089528 @default.
• W192179675 hasConceptScore W192179675C86803240 @default.

• next